13535-03-0

Basic information

• Product Name: 4-(Acetylamino)-3-bromopyridine
• Synonyms: 4-(Acetylamino)-3-bromopyridine
• CAS NO: 13535-03-0
• Molecular Formula: C7H7BrN2O
• Molecular Weight: 215.05
• Mol File: 13535-03-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 102-103 °C
• Boiling Point: 365.0±27.0 °C(Predicted)
• Appearance: /
• Density: 1.630±0.06 g/cm3(Predicted)
• PKA: 12.97±0.70(Predicted)
• CAS DataBase Reference: 4-(Acetylamino)-3-bromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Acetylamino)-3-bromopyridine(13535-03-0)
• EPA Substance Registry System: 4-(Acetylamino)-3-bromopyridine(13535-03-0)

Safety Data

• Hazardous Substances Data: 13535-03-0(Hazardous Substances Data)

Upstream product

• 13534-98-0 3-bromopyridin-4-amine 
• 108-24-7 acetic anhydride 
• 1678-49-5 3-Bromo-4-nitropyridine N-oxide 
• 75-36-5 acetyl chloride 
• 5221-42-1 4-acetylaminopyridine 

Downstream Products

• 271-34-1 5-azaindole 

Relevant articles and documents

Synthesis of 3-hetarylpyrroles by Suzuki–Miyaura cross-coupling

1-[tert-Butyl(diphenyl)silyl]pyrrol-3-ylboronic acid was obtained from pyrrole in three steps. Its Suzuki–Miyaura cross-coupling with functionalized pyridinyl and pyrimidinyl bromides afforded new promising 3-hetaryl-1H-pyrroles.

BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS

The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors,and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as M

Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure-activity relationships, physicochemical properties and biological activity

The discovery, synthesis and structure-activity relationship (SAR) of a novel series of cannabinoid 1 (CB1) and cannabinoid 2 (CB 2) receptor ligands are reported. Based on the aminoalkylindole class of cannabinoid receptor agonists, a biphenyl moiety was introduced as novel lipophilic indole 3-acyl substituent in 11-16. Furthermore, the 3-carbonyl tether was replaced with a carboxamide linker in 17-20 and the azaindole (pyrrolopyridine) nucleus was designed as indole bioisostere with improved physicochemical properties in 21-25. Through these SAR efforts, several high affinity CB1/CB2 dual cannabinoid receptor ligands were identified. Indole-3-carboxamide 17 displayed single-digit nanomolar affinity and ～80 fold selectivity for CB1 over the CB2 receptor. The azaindoles displayed substantially improved physicochemical properties (lipophilicity; aqueous solubility). Azaindole 21 elicited potent cannabinoid activity. Cannabinoid receptor agonists 17 and 21 potently modulated excitatory synaptic transmission in an acute rat brain slice model of cannabinoid receptor-modulated neurotransmission.